menu

Part 1: Improving Quality of Care and Shared Decision-Making in Myelofibrosis

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Part 1: Improving Quality of Care and Shared Decision-Making in Myelofibrosis

close
0.50 credits
30 miuntes
Part 1: Improving Quality of Care and Shared Decision-Making in Myelofibrosis
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    The only potentially curative therapy for Myelofibrosis (MF) is hematopoietic stem cell transplantation (HSCT), applicable only to patients with a compatible donor, and of suitable age and functional status to withstand treatment-related toxicity. The JAK inhibitor ruxolitinib has been the mainstay of MF treatment since it was approved in 2011, and until recently was the only targeted agent approved by the US Food & Drug Administration for management of MPNs. The recent addition of a novel JAK inhibitor, the JAK2-selective fedratinib, is a significant milestone in the therapeutic landscape of MF.

    Despite this critical advancement, MF management is suboptimal, owing to a lack of clinician awareness of the substantial symptom burden and quality-of-life impact of MF. The development of individualized care concepts have changed with increasing understanding of the role of HSCT, JAK inhibitors, and other patient-/disease-specific factors in the treatment paradigm for MF.

    This activity will review recent advances and critical concepts that affect outcomes, including symptom burden, molecular diagnostics, prognostic risk stratification scores, and the treatment and management of MF.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Summarize myelofibrosis disease burden and impact on patients’ quality of life
    • Apply guideline-recommended evidence-based prognostic and risk stratification approaches in clinical practice 
    • Evaluate clinical safety and efficacy data, including data pertaining to quality of life measures, for approved and emerging therapeutic agents
    • Develop personalized care and treatment plans that incorporate disease- and patient-specific factors
  • Target Audience

    This activity is intended for hematologists, oncologists, physician assistants, nurse practitioners, pharmacists, dieticians, social workers, and other healthcare practitioners who are part of the care team that treats or manages patients with myelofibrosis.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires instructors, planners, managers, reviewers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Ruben A. Mesa, MD, FACP, reported a financial interest/relationship or affiliation in the form of Research grant, Incyte Corporation, Celgene Corporation, CTI BioPharma, AbbVie.; Received income in any amount from, Novartis Pharmaceuticals Corporation, Sienna Biopharmaceuticals, Inc.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS;  Joseph Kim, MD, MPH, MBA;  Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Adrienne N. Nedved, PharmD, MPA, BCOP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. 

  • Accreditation and Credit Designation Statements

    CONTINUING MEDICAL EDUCATION
    Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Q Synthesis LLC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/19/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-9999-20-040-H01-P. 

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Certified Dietitians
    AXIS Medical Education is a Joint Acrreditation Provider which includes Continuing Professional Education (CPE) with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 0.5 Continuing Professional Education units (CPEUs) for completion of this activity.

  • Provider(s)/Educational Partner(s)

    Jointly provided by

  • Commercial Support

    This program is supported by an independent medical education grant from Celgene Corporation.

  • Terms of Use

    Disclosure of Unlabeled Use     
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer     
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:  
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    The only potentially curative therapy for Myelofibrosis (MF) is hematopoietic stem cell transplantation (HSCT), applicable only to patients with a compatible donor, and of suitable age and functional status to withstand treatment-related toxicity. The JAK inhibitor ruxolitinib has been the mainstay of MF treatment since it was approved in 2011, and until recently was the only targeted agent approved by the US Food & Drug Administration for management of MPNs. The recent addition of a novel JAK inhibitor, the JAK2-selective fedratinib, is a significant milestone in the therapeutic landscape of MF.

    Despite this critical advancement, MF management is suboptimal, owing to a lack of clinician awareness of the substantial symptom burden and quality-of-life impact of MF. The development of individualized care concepts have changed with increasing understanding of the role of HSCT, JAK inhibitors, and other patient-/disease-specific factors in the treatment paradigm for MF.

    This activity will review recent advances and critical concepts that affect outcomes, including symptom burden, molecular diagnostics, prognostic risk stratification scores, and the treatment and management of MF.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Summarize myelofibrosis disease burden and impact on patients’ quality of life
    • Apply guideline-recommended evidence-based prognostic and risk stratification approaches in clinical practice 
    • Evaluate clinical safety and efficacy data, including data pertaining to quality of life measures, for approved and emerging therapeutic agents
    • Develop personalized care and treatment plans that incorporate disease- and patient-specific factors
  • Target Audience

    This activity is intended for hematologists, oncologists, physician assistants, nurse practitioners, pharmacists, dieticians, social workers, and other healthcare practitioners who are part of the care team that treats or manages patients with myelofibrosis.

  • Faculty Disclosure

    Disclosure of Conflict of Interest 
    AXIS Medical Education requires instructors, planners, managers, reviewers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity. Ruben A. Mesa, MD, FACP, reported a financial interest/relationship or affiliation in the form of Research grant, Incyte Corporation, Celgene Corporation, CTI BioPharma, AbbVie.; Received income in any amount from, Novartis Pharmaceuticals Corporation, Sienna Biopharmaceuticals, Inc.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS;  Joseph Kim, MD, MPH, MBA;  Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Adrienne N. Nedved, PharmD, MPA, BCOP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. 

  • Accreditation and Credit Designation Statements

    CONTINUING MEDICAL EDUCATION
    Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Q Synthesis LLC. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

    This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 11/19/2021. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.5 contact hour of continuing pharmacy education credit JA4008106-9999-20-040-H01-P. 

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Certified Dietitians
    AXIS Medical Education is a Joint Acrreditation Provider which includes Continuing Professional Education (CPE) with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 0.5 Continuing Professional Education units (CPEUs) for completion of this activity.

  • Provider(s)/Educational Partner(s)

    Jointly provided by

  • Commercial Support

    This program is supported by an independent medical education grant from Celgene Corporation.

  • Terms of Use

    Disclosure of Unlabeled Use     
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Disclaimer     
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:  
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 4/21/21